Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Psychedelics startup Nue Life Health rolls out free version of its ketamine therapy tracking app

From TechCrunch

By Mike Butcher

June 15, 2023

Psychedelics startup Nue Life Health rolls out free version of its ketamine therapy tracking app

Psychedelics startup Nue Life Health rolls out free version of its ketamine therapy tracking app

Nue Life Health is a U.S.-based telemedicine startup that combines psychedelic-assisted therapies and a health tracking app. Previously, the app was only offered as part of its own internal service. However, the startup is now opening up its “Nue app” and its “Nue score” available for free to any patient undergoing ketamine therapy, not just its own. The FDA has approved a variant of Ketamine called “Esketamine” as a medication for depression.

The Nue Life app allows patients undergoing ketamine therapy in the U.S. to join Nue Life’s membership services to complement their drug therapy. The app has biometric data integration (Apple Healthkit and Google Fit), and accesses the ‘Nue Score’ progress tracking. The at-home ketamine therapy combines music therapies and a data-led, ‘quantified self’ approach.

All users in the United States who are undergoing ketamine therapy across all treatment modalities, including via lozenges, intramuscular (IM) and intravenous (IV), will be able to access the Nue Life app.

As a result, it’s likely that this will expand Nue Life’s market reach, as it rolls out these new services.

Last year Nue Life said raised a $23 million Series A equity financing led by Obvious Ventures (co-founded by Ev Williams, co-founder of Twitter), which was part venture debt and part equity. This followed a seed round in 2021.

The company has also now completed an extra $1.9m financing round from existing investors to back the app roll-out for free.

Nue Life says it now delivers “at-home” ketamine therapy to over eight thousand patients across the U.S. combined with libraries, apps, and aftercare programs.

In a statement, Nue Life co-founder and CEO Juan Pablo Cappello said: “We have seen that patients who take advantage of our full program experience a 20-30% improvement over the baseline of drug-only therapy. We are now excited to make all these tools, content and preparation and after-care programs available to all users that may be undergoing ketamine treatment with providers across the US, including at-home or within clinics or offices.”

Nue Life has also appointed Dr. Frank Drummond as its new Chief Medical Officer. Dr. Drummond was formerly the national CMO of HCA’s behavioral health practice.

Nue Life competes with Mindbloom, as well as Field Trip Health, which also has physical treatment centers.

In March this year, TechCrunch interviewed Mindbloom’s CEO Dylan Beynon about how he saw the future of psychedelic mental health.

Psychedelics startup Nue Life Health rolls out free version of its ketamine therapy tracking app by Mike Butcher originally published on TechCrunch

Most Recent

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

AI infrastructure company Infinity announced Monday a $15 million raise at a $100 million valuation from investors including Touring Capital, Principal VC, and researchers from companies such as OpenAI and Anthropic.

Jul 20, 2026

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

For the first time since 2024, StrictlyVC is coming back to New York City — and we're bringing the kind of access you’d expect from an under-wraps event to the whole startup, VC, and dealmaking community.

Jul 20, 2026

Neil Rimer thinks the AI money is coming back out

Neil Rimer thinks the AI money is coming back out

Neil Rimer, the venture capitalist who co-founded Index Ventures, predicts the historic wealth AI is generating in Silicon Valley will have to be redistributed, voluntarily or involuntarily.

Jul 17, 2026

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks has remade its image into an AI company and has published research on the cost savings of open-weight AI models for coding.

Jul 17, 2026

Similar Posts

Kevin Hart’s VC firm leads $35M Series B for weight-loss app Simple

Kevin Hart’s VC firm leads $35M Series B for weight-loss app Simple

Simple is an AI-powered health coaching app that helps people lose weight.

Oct 1, 2025

Stellar Sleep app gets initial funding to awaken root cause of chronic insomnianin users

Stellar Sleep app gets initial funding to awaken root cause of chronic insomnianin users

Stellar Sleep’s mobile app taps into psychological methods to help users breaknthe cycle of those frequent nights awake.

Feb 6, 2024

Lotus Health nabs $35M for AI doctor that sees patients for free

Lotus Health nabs $35M for AI doctor that sees patients for free

This AI doctor is licensed in all 50 states, the startup says. The deal was led by CRV and Kleiner Perkins.

Feb 3, 2026

Visible wants to track your illness, more than your fitness

Visible wants to track your illness, more than your fitness

There’s no shortage of health and fitness trackers — the list of suppliers is asnlong as my arm, ranging from the mainstream (Apple, Google, Samsung, Fitbit,nWithings) to the more esoteric and specialized (Polar, Suunto, Garmin). Thenassumption underpinning each of those devices is that you’re more or lessnhealthy, and wanting to get […]

Jan 29, 2024

Most Recent

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

AI infrastructure company Infinity announced Monday a $15 million raise at a $100 million valuation from investors including Touring Capital, Principal VC, and researchers from companies such as OpenAI and Anthropic.

Jul 20, 2026

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

For the first time since 2024, StrictlyVC is coming back to New York City — and we're bringing the kind of access you’d expect from an under-wraps event to the whole startup, VC, and dealmaking community.

Jul 20, 2026

Neil Rimer thinks the AI money is coming back out

Neil Rimer thinks the AI money is coming back out

Neil Rimer, the venture capitalist who co-founded Index Ventures, predicts the historic wealth AI is generating in Silicon Valley will have to be redistributed, voluntarily or involuntarily.

Jul 17, 2026

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks has remade its image into an AI company and has published research on the cost savings of open-weight AI models for coding.

Jul 17, 2026

Similar Posts

Kevin Hart’s VC firm leads $35M Series B for weight-loss app Simple

Kevin Hart’s VC firm leads $35M Series B for weight-loss app Simple

Simple is an AI-powered health coaching app that helps people lose weight.

Oct 1, 2025

Stellar Sleep app gets initial funding to awaken root cause of chronic insomnianin users

Stellar Sleep app gets initial funding to awaken root cause of chronic insomnianin users

Stellar Sleep’s mobile app taps into psychological methods to help users breaknthe cycle of those frequent nights awake.

Feb 6, 2024

Lotus Health nabs $35M for AI doctor that sees patients for free

Lotus Health nabs $35M for AI doctor that sees patients for free

This AI doctor is licensed in all 50 states, the startup says. The deal was led by CRV and Kleiner Perkins.

Feb 3, 2026

Visible wants to track your illness, more than your fitness

Visible wants to track your illness, more than your fitness

There’s no shortage of health and fitness trackers — the list of suppliers is asnlong as my arm, ranging from the mainstream (Apple, Google, Samsung, Fitbit,nWithings) to the more esoteric and specialized (Polar, Suunto, Garmin). Thenassumption underpinning each of those devices is that you’re more or lessnhealthy, and wanting to get […]

Jan 29, 2024